New ultrasound drug delivery safe, reduces side effects
The new system, being developed by a team of Stanford University researchers, uses nanoparticles to encapsulate drugs along with ultrasound to unleash the drugs at their intended destinations.
In a study published in the journal Nature Nanotechnology, the team showed in rats that their system can deliver ketamine to specific regions of the brain and painkillers to specific nerves in limbs. Using a new sucrose formulation, they found that nanoparticles are safer, more stable, and easier to produce.
'Turns out just a little bit of sugar is all you need to make this work,' said Raag Airan, Assistant Professor of radiology, Stanford Medicine.
The researchers found that a 5 per cent sucrose solution inside the nanoparticles made them relatively stable in the body, yet responsive to ultrasound stimulation.
That means that even when the nanoparticles are delivered into the bloodstream and travel throughout the body, most of the drug is released only where it's needed. A narrow beam of ultrasound, externally applied, pinpoints the target, releasing the drug.
Such a system has the potential to make a wide range of drugs safer and more effective.
'We can maximise the therapeutic effect and minimise the off-target effects,' Airan said.
Initially, the nanoparticles consisted of a polymer shell filled with a liquid core of uncommon chemical compounds. But as it did not work, the team tried adding a variety of common substances to the liquid core, from polymers to salts, to modulate its response to ultrasound.
Finally, they tried sugar. After testing different types and concentrations of sugars, the researchers found that 5 per cent sucrose added to the liquid core achieved the best balance of ultrasound response and stability at body temperature.
The researchers then tested the drug delivery system in rats, comparing animals that were given an injection of free, unencapsulated ketamine with those given ketamine encapsulated in nanoparticles with 5 per cent sucrose.
When the researchers applied ultrasound to a particular brain region, the nanoparticles delivered about three times as much drug to that region as to other parts of their brain -- demonstrating targeted drug release.
If the system works in humans, clinicians may be able to isolate the emotional effects of ketamine -- to treat depression, for example -- while blocking the dissociative effects of the drug, the researchers said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
a day ago
- Hindustan Times
Seeing Silicon: A bot to tackle blood clots
When I first saw a demo of the milli-spinner in Stanford Robotics Center, it reminded me of a 1966 film Fantastic Voyage in which a submarine crew is shrunk to microscopic size and ventures into the body of an injured scientist to repair the damage to his brain. Except scientists at the Stanford University imagined a more efficient way of dispensing targeted drug inside a human body – a worm-sized robot that can travel through veins and compress a blood clot, treating strokes and heart attacks. The milli-spinner prototype takes up a small display in the medical robotics room. What looms in the room when I enter are larger robots used for imaging and surgery. The millirobot in comparison is less than one centimeter in size. It moves like a tiny worm inside a web of transparent tubes, controlled by a magnetic field. The hollow tube, barely visible unless you bend closer and have a look, rotates rapidly using a series of slits. It was this movement that took mechanical engineer Dr Renee Zhao, the head of the lab and the creator of the robot, years to master. The movement made all the difference. 'With existing technology, there was no way to reduce the size of a blood clot. They relied on deforming and rupturing the clot to remove it,' explains Dr Zhao, assistant professor of mechanical engineering. Once they got the spinning right, the milli-spinner could enter the body through a catheter, draw the clot and compress it before suctioning it out. In a recent scientific paper published in Nature in June 2025, Dr Zhao and her team showed that this new approach to technology – compression before suction - outperformed available treatments in removal of clots from human bloodstream. 'At first, we simply wondered whether this suction could help remove a blood clot,' Zhao said. 'But when we tested the spinner on a clot, we observed a dramatic reduction in volume. Honestly, it felt like magic.' Also Read: Seeing Silicon | Is this year the beginning of the end of smartphones? The more I see and read about the upcoming technologies in medical devices, the more magical it does feel. Stanford's not the first one to develop millirobots, though Zhao has a lot of experience working on millirobots. After the microelectronic advances in the early 2000s, microfabrication allowed engineers to create intricate mechanical and electronic components on a microscopic scale. Due to their small size, microrobots (about one centimetre) and millirobots (less than one centimetre) could be made cheap and could be used in large numbers – like in swarm robotics. However, there was one challenge, and it took technologists another decade to solve it. How do you make these millirobots move through the body without them being tethered to a power source? The microrobots came with small lightweight battery sources but it wasn't enough for them to navigate inside blood vessels or reach hard to reach places. (Just like Fantastic Voyage shows, our blood vessels are complicated rivers to navigate). It was with Wi-Fi, another technology that has dramatically changed our lives, that scientists finally figured out how to control the device inside the body. This level of control meant that these millirobots could become quite useful to deliver precision medicine inside the human body. They could also be used to minimally invasive surgery, diagnostics or navigating blood vessels for treatment. The last decade has seen a flurry of experiments in medical millirobots, the Stanford experiment being one of the latest successful examples of the technology. Some of them have already made it to our hospitals and treatment. For example, biohybrid microswimmers which are created using bacteria, microalgae have been used for advanced medical functions – like targeted therapy of tumours. But most innovations are still in laboratories of research institutions. The next level to these kinds of robots is xenobots, the world's first living robots – built from the heart muscle and stem cells harvested from an early African frog embryo. These AI-designed robots are less than 1 millimetre wide, can simulate a specific task and can work in swarms. They use energy from fat and protein naturally stored in their tissue, which lasts about a week at which point they simply turn into dead skin cells. Future possible uses are treating individuals by creating xenobots using their own cells (reducing the immune response challenge with bots inside your body) and even to aggregate tiny bits of ocean-polluting microplastics into a large ball of plastic to recycle. The latest biorobotics does feel like magic rather than technology, just as Dr Zhao felt when she saw the milli-spinner compress the blood clot. More and more, the technological advances in biomedicine do sound like alchemy to me. Shweta Taneja is an author and journalist based in the Bay Area. Her fortnightly column will reflect on how emerging tech and science are reshaping society in Silicon Valley and beyond. Find her online with @shwetawrites. The views expressed are personal.
Hans India
2 days ago
- Hans India
New ultrasound drug delivery safe, reduces side effects
New Delhi: US researchers are building a non-invasive system using ultrasound to deliver drugs anywhere in the body with precision, as well as with reduced side effects. The new system, being developed by a team of Stanford University researchers, uses nanoparticles to encapsulate drugs along with ultrasound to unleash the drugs at their intended destinations. In a study published in the journal Nature Nanotechnology, the team showed in rats that their system can deliver ketamine to specific regions of the brain and painkillers to specific nerves in limbs. Using a new sucrose formulation, they found that nanoparticles are safer, more stable, and easier to produce. 'Turns out just a little bit of sugar is all you need to make this work,' said Raag Airan, Assistant Professor of radiology, Stanford Medicine. The researchers found that a 5 per cent sucrose solution inside the nanoparticles made them relatively stable in the body, yet responsive to ultrasound stimulation. That means that even when the nanoparticles are delivered into the bloodstream and travel throughout the body, most of the drug is released only where it's needed. A narrow beam of ultrasound, externally applied, pinpoints the target, releasing the drug. Such a system has the potential to make a wide range of drugs safer and more effective. 'We can maximise the therapeutic effect and minimise the off-target effects,' Airan said. Initially, the nanoparticles consisted of a polymer shell filled with a liquid core of uncommon chemical compounds. But as it did not work, the team tried adding a variety of common substances to the liquid core, from polymers to salts, to modulate its response to ultrasound. Finally, they tried sugar. After testing different types and concentrations of sugars, the researchers found that 5 per cent sucrose added to the liquid core achieved the best balance of ultrasound response and stability at body temperature. The researchers then tested the drug delivery system in rats, comparing animals that were given an injection of free, unencapsulated ketamine with those given ketamine encapsulated in nanoparticles with 5 per cent sucrose. When the researchers applied ultrasound to a particular brain region, the nanoparticles delivered about three times as much drug to that region as to other parts of their brain -- demonstrating targeted drug release. If the system works in humans, clinicians may be able to isolate the emotional effects of ketamine -- to treat depression, for example -- while blocking the dissociative effects of the drug, the researchers said.
Indian Express
4 days ago
- Indian Express
How scientists built a password-protected mind-reading brain implant
Scientists have developed a brain-computer interface (BCI) — a device that allows the human brain to communicate with external software or hardware — which works only when the user thinks of a preset password. The findings were detailed in a study, 'Inner speech in motor cortex and implications for speech neuroprostheses', published in the journal Cell on August 14. The new system was developed by researchers based at Stanford University (the United States). Here is a look at how scientists built a password-protected BCI. But first, why are brain-computer interfaces significant? BCIs allow the user to control an application or a device using only their mind. Usually, when someone wants to interact with an application — let's say, they want to switch on a lamp — they first have to decide what they want to do, then they coordinate and use the muscles in their arms, legs or feet to perform the action — like pressing the lamp's on/off switch with their fingers. Then, the device — in this case, the lamp — responds to the action. What BCIs do is help skip the second step of coordinating and using the muscles to perform an action. Instead, they use a computer to identify the desired action and then control the device directly. This is the reason why BCIs have emerged as promising tools for people with severe physical disabilities. They are also being used to restore speech in people who have limited reliable control over their muscles. How was a password-protected BCI developed? The researchers involved in the study focused on 'internal-speech' BCIs, which translate brain signals into text or audio. While these types of devices do not require users to speak out loud, there is always a risk that they could accidentally decode sentences users never intended to say. To resolve this issue, the researchers first 'analysed brain signals collected by microelectrodes placed in the motor cortex — the region involved in voluntary movements — of four participants,' according to a report by the journal Nature. All of these participants had trouble speaking and were asked to either try to say a set of words or imagine saying them. The researchers then analysed the recordings of participants' brain activity. This helped them discover that attempted and internal speech originated in the same brain region and generated similar neural signals, but those associated with internal speech were weaker. This data was used to train artificial intelligence models, which helped BCIs to interpret sentences imagined by the participants after they were asked to think of specific phrases. The devices correctly interpreted 74% of the imagined sentences. To ensure that the BCIs do not decode sentences that users do not intend to utter, the researchers added a password to the system, allowing users to control when decoding began. 'When a participant imagined the password 'Chitty-Chitty-Bang-Bang' (the name of an English-language children's novel), the BCI recognised it with an accuracy of more than 98%,' the Nature report said. (With inputs from Nature)
